BioXcel’s Serenity Trial: At-Home Agitation Treatment
BioXcel Therapeutics has reached 33% enrollment (67 patients) in its 200-patient Phase 3 SERENITY At-Home trial for BXCL501 (dexmedetomidine...
eClinical Tech News
Regeneron and Sanofi: Dupixent® Bullous Pemphigoid Data at AAD
Regeneron and Sanofi announced positive Phase 2/3 trial results for Dupixent (dupilumab) in treating moderate-to-severe bullous pemphigoid (BP), a...
Late-Breaking ESK-001 Phase 2 Data Presented at AAD Meeting
Alumis announced positive 52-week data from the open-label extension of its Phase 2 STRIDE trial for ESK-001, an oral...
Study Shows Increased Cardiometabolic Risk After Switching to Integrase Inhibitors
The AIDS Clinical Trials Group (ACTG) presented data from the REPRIEVE study at the 2025 Conference on Retroviruses and...
aTyr Pharma’s EFZOFITIMOD Shows Promise in Sarcoidosis Treatment
aTyr Pharma’s Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis received a positive safety review from an independent...
Chemomab’s Nebakitug Shows Promise in Systemic Sclerosis Treatment
Chemomab Therapeutics announced new scientific data supporting the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis...
Sernova Secures $1M Convertible Debt Financing
Sernova Biotherapeutics secured a CAD$1,000,000 convertible debenture financing from existing shareholder and board member, Dr. Steven Sangha. The proceeds...
Journey Medical’s Emrosi™ Rosacea Trial Results Published in JAMA Dermatology
Journey Medical Corporation announced positive Phase 3 trial results for its rosacea treatment, Emrosi (DFD-29), published in JAMA Dermatology....
Vaxart’s Oral Norovirus Vaccine Shows Promise in Elderly Adults
Vaxart, Inc. announced complete data from a Phase 1b trial of its oral norovirus vaccine candidate in older adults,...
Tenax Advances Oral Levosimendan in Phase 3 PH-HFpEF Studies
Tenax Therapeutics announced the FDA’s acceptance of an amendment to expand its Phase 3 LEVEL study for TNX-103 (oral...